Director dealings: Smith & Nephew executives offload shares

Smith & Nephew

Medical technology company Smith & Nephew disclosed two executive share sales on Wednesday, with its shares remaining flat after the announcement.

Smith & Nephew

07 May 2024 11:55:21

Source: Sharecast

Phil Cowdy, its chief corporate development and corporate affairs officer, sold 12,083 shares on 27 April for £12.83280 each, resulting in a total value of £155,058.72.

Following the sale, Cowdy still held 49,000.99390 ordinary shares, equivalent to 0.00558% of its issued share capital.

Bradley Cannon, the company’s president of global orthopaedics, meanwhile sold 9,500 shares on 2 May at a price of £12.926813 apiece, resulting in a total value of £122,804.72.

After the transaction, Cannon still held 117,819.37494 shares, or 0.01342% of the firm’s issued capital.

Both individuals still maintained a shareholding in line with the company's guidelines after the sale, the board confirmed.

Elsewhere, NB Private Equity Partners saw its shares rise after non-executive director Trudi Clark made a small share purchase.

Clark purchased 1,247 shares at a price of 15.9p, for a total value of £19,827.30.

At 1427 BST, shares in Smith & Nephew were flat at 1,298p, while those in NB Private Equity Partners were up 1.69% at 120p.

Reporting by Josh White for Sharecast.com.

Exchange: London Stock Exchange
Sell:
0.00
Buy:
0.00
Change:
81.12
(0.99%)
Date:
Prices delayed by at least 15 minutes

Compare our accounts

Whether you're looking for a Share Dealing Account, Stocks and Shares ISA or a Self-Invested Personal Pension (SIPP), we've got an account to suit your needs.

IWeb is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.